Knight Therapeutics Inc., 2025
Acting for Knight Therapeutics Inc. in its C$120-million acquisition of substantially all of the assets of Paladin Pharma Inc. to expand its Canadian business.
The push for innovation drives both scientific discovery and transformative business strategies. Whether you’re an industry leader or a new market entrant, you want creative thinking and a clear path to future growth – and that’s exactly what our dedicated lawyers deliver.
Innovators and investors across the life sciences sector rely on our multidisciplinary team for help in tackling highly complex transactions and legal issues. From biotech firms to medical device manufacturers, and from private equity investors to pharmaceutical giants, we work with all industry players to help navigate the daunting business challenges that arise where innovation and regulation intersect.
At any stage in the life cycle, from the creation of a promising new therapy through commercialization, product licensing and regulatory compliance, and whether negotiating strategic alliances or a complex global merger, we have the sector expertise and experience to develop strategies and solutions that work.
Acting for Knight Therapeutics Inc. in its C$120-million acquisition of substantially all of the assets of Paladin Pharma Inc. to expand its Canadian business.
Acting as Canadian counsel to Bain Capital, a leading global private investment firm, in its US$3.3 billion acquisition of Mitsubishi Tanabe Pharma Corporation, a Japanese pharmaceutical company.